Allopregnanolone and mood disorders

  title={Allopregnanolone and mood disorders},
  author={T. B{\"a}ckstr{\"o}m and M. Bixo and M. Johansson and S. Nyberg and G. Wingen},
  journal={Progress in Neurobiology},
  • T. Bäckström, M. Bixo, +2 authors G. Wingen
  • Published 2014
  • Medicine
  • Progress in Neurobiology
  • UNLABELLED Certain women experience negative mood symptoms during the menstrual cycle and progesterone addition in estrogen treatments. In women with PMDD increased negative mood symptoms related to allopregnanolone increase during the luteal phase of ovulatory menstrual cycles. In anovulatory cycles no symptom or sex steroid increase occurs. This is unexpected as positive modulators of the GABA-A receptor are generally increasing mood. This paradoxical effect has brought forward a hypothesis… CONTINUE READING
    111 Citations

    Paper Mentions

    Observational Clinical Trial
    The aim of the proposed research is to identify the clinical and biological phenotypes that define perinatal anxiety. The importance of this research to public health is that it will… Expand
    ConditionsPerinatal Anxiety
    Allopregnanolone and reproductive psychiatry: an overview
    • 7
    The role of ovarian hormone-derived neurosteroids on the regulation of GABAA receptors in affective disorders
    • 41
    • Highly Influenced
    Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice
    Progesterone, reproduction, and psychiatric illness.
    GABAA dysregulation as an explanatory model for late-onset postpartum depression associated with weaning and resumption of menstruation
    • 5
    • Highly Influenced
    • PDF


    The Role of Hormones and Hormonal Treatments in Premenstrual Syndrome
    • 145
    • PDF
    Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: A pilot study
    • 125
    Progesterone selectively increases amygdala reactivity in women
    • 201
    • PDF
    Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome
    • 49
    • PDF
    Pharmacokinetic and behavioral effects of allopregnanolone in healthy women
    • 117
    • PDF
    Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.
    • 591
    Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences.
    • 348
    • PDF